The long term objective of this application is to define the relationship between infant respiratory syncytial virus (RSV) infection and the host response that enables asthma inception. There is abundant evidence that children who experience severe RSV bronchiolitis during infancy are at greater risk for developing asthma later in childhood;however the host and viral determinants of severity of illness are not fully defined. Also unknown is whether mild RSV-induced illness in infancy may protect against the subsequent development of childhood asthma. In Project 1, we utilize the ReSPIRA (Respiratory Study for Protection of Infants from RSV to Asthma) cohort of 2000 infants to focus on host immune responses to RSV infection and the subsequent risk of recurrent wheezing and childhood asthma. Specifically, in Project 1 we will a) establish the relationship between the host phenotypic response to RSV infection in the first 6 months of life and the risk of recurrent wheeze and asthma, and b) identify the host genetic and immune response determinants of the RSV infection phenotype that affect the development of early childhood wheezing and asthma following RSV infection. In Project 2, we will focus on the contribution of specific RSV strains to early childhood wheezing and asthma development. RSV strains isolated from the ReSPIRA cohort will be genotyped and clinical parameters such as bronchiolitis severity score, as well as mediators of the host immune response measured in respiratory secretions will be studied to determine how RSV genotypes impact the host response. In Project 3, we will utilize a mouse model of RSV infection to examine the role of the prostaglandin 12 (PGI2) on airway dysfunction of an RSV strain (01/2-20) that has been associated with severe infant bronchiolitis and which induces airway pathology in the mouse. We previously reported that PG12 and signaling through its receptor (IP) is a critical determinant of severity of illness in RSV strain A2 infection. This project will determine the role of host PGI2 in RSV airway pathogenesis and also determine if a PGI2 analog currently used in the treatment of human disease is a target for RSV bronchiolitis. Further, in Project 3, we will use RSV strains isolated from ReSPIRA in Project 2 to determine the generalizability of PGI2 as a therapeutic target.

Public Health Relevance

PUBLIC HEATH RELEVANCE (provided by applicant): RSV is the leading cause of bronchiolitis and causes >100,000 infant hospitalizations in the US each year. Studies have also revealed that severe RSV infection in infancy is associated with the later development of childhood asthma. This application will examine the effects of both host genetic and immune response determinants, as well as the influence of specific RSV strains, on severity of RSV bronchiolitis and childhood asthma. In addition, we will define the role of a novel therapeutic target, PG12, in RSV pathogenesis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI095227-01
Application #
8164372
Study Section
Special Emphasis Panel (ZAI1-PA-I (M1))
Program Officer
Davidson, Wendy F
Project Start
2011-08-01
Project End
2016-07-31
Budget Start
2011-08-01
Budget End
2012-07-31
Support Year
1
Fiscal Year
2011
Total Cost
$1,850,505
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Wurth, Mark A; Hadadianpour, Azadeh; Horvath, Dennis J et al. (2018) Human IgE mAbs define variability in commercial Aspergillus extract allergen composition. JCI Insight 3:
Toki, Shinji; Zhou, Weisong; Goleniewska, Kasia et al. (2018) Endogenous PGI2 signaling through IP inhibits neutrophilic lung inflammation in LPS-induced acute lung injury mice model. Prostaglandins Other Lipid Mediat 136:33-43
Bloodworth, Melissa H; Rusznak, Mark; Bastarache, Lisa et al. (2018) Association of ST2 polymorphisms with atopy, asthma, and leukemia. J Allergy Clin Immunol 142:991-993.e3
Brunwasser, Steven M; Gebretsadik, Tebeb; Gold, Diane R et al. (2018) A new model of wheezing severity in young children using the validated ISAAC wheezing module: A latent variable approach with validation in independent cohorts. PLoS One 13:e0194739
Celada, Lindsay J; Kropski, Jonathan A; Herazo-Maya, Jose D et al. (2018) PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-?1 production. Sci Transl Med 10:
Donovan, Brittney M; Ryckman, Kelli K; Breheny, Patrick J et al. (2018) Association of newborn screening metabolites with risk of wheezing in childhood. Pediatr Res 84:619-624
Turi, Kedir N; Shankar, Jyoti; Anderson, Larry J et al. (2018) Infant Viral Respiratory Infection Nasal Immune-Response Patterns and Their Association with Subsequent Childhood Recurrent Wheeze. Am J Respir Crit Care Med 198:1064-1073
Stone Jr, Cosby A; McEvoy, Cindy T; Aschner, Judy L et al. (2018) Update on Vitamin E and Its Potential Role in Preventing or Treating Bronchopulmonary Dysplasia. Neonatology 113:366-378
Tashkin, Donald P; Peebles Jr, R Stokes (2018) Controversies in Allergy: Is Asthma Chronic Obstructive Pulmonary Disease Overlap a Distinct Syndrome That Changes Treatment and Patient Outcomes? J Allergy Clin Immunol Pract :
Stone Jr, Cosby A; Hemler, Jonathan A; Commins, Scott P et al. (2018) Reply. J Allergy Clin Immunol 141:1957-1958

Showing the most recent 10 out of 111 publications